NOVAVAX, a biotechnology company developing next-generation vaccines for serious infectious disease, today announced its financial results and operational highlights for the first quarter of 2021.
Final efficacy analysis of UK Phase 3 Clinical trial of Covovax by Novavax confirmed the following information: 100 percent protection against severe Covid -19, 96.4 percent efficacy against original strain of Covid-19, 86.3 percent efficacy against B.1.1.7 UK variant, 90.9 percent efficacy in adults with high-risk medical comorbidities, 88.9 percent efficacy in adults over the age of 65 years old, 55.4 percent efficacy among HIV-negative participants, with the vast majority of cases due to the B.1.351 South Africa escape variant and 100 percent protection against severe diseases caused by South Africa and UK variants
Continue reading with one of these options:
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)